Companies / XEN

XENITRA LIMITED

ASX:XENConsumer Discretionary Distribution & Retail
4.28B shares on issueASX (delayed) · as of 28 July 2026$0.003price · delayed$10.7Mmarket cap · indicative
C
Dilution grade

Runway under 2 quarters; options/rights overhang 47% of shares; share count grew 11% in 24 months

Cash runway1.0 quarters of funding
Share-count growth (24m)10.8%
Raise cadence (24m)1 cash raise
Options & rights overhang46.7% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

XENITRA LIMITED's ordinary share count grew 10.8% between April 2026 and May 2026 to 4.28B shares. The company raised capital once in the 24-month window for total proceeds of A$1.2M, with the most recent raise in May 2026 reporting proceeds of A$1.2M. Options and rights could convert into 2.00B new shares, equal to 46.7% of the current share count, of which 0% are in the money; the nearest expiry is October 2026. At the March 2026 quarter XENITRA reported A$1.3M in available cash, covering 1.0 quarters at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
46.7%
Max option dilution
0.0%
ITM option dilution
1
Raises · last 12 months
1.0 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 4.28B per ASX (delayed) (28 July 2026).
3.94B4.06B4.19BMar 26May 26July 26Cash raise · 4 May 2026

Cash runway

1.0 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$1.3M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
19 May 20262A · quoted issueXEN : ORDINARY FULLY PAID4.28BAppendix 2A
8 Apr 20262A · quoted issueXEN : ORDINARY FULLY PAID3.86BAppendix 2A
6 Apr 20263G · unquotedXEN : ORDINARY FULLY PAID3.85BAppendix 3G
6 Apr 20263G · unquotedXEN : ORDINARY FULLY PAID3.85BAppendix 3G
6 Apr 20263G · unquotedXEN : ORDINARY FULLY PAID3.85BAppendix 3G
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

1 cash raise in the last 24 months · 1 in the last 12 months

$1.3M
Capital raise
4 May 2026
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

46.7%
Total overhang · of current shares
0.0%
In the money · at current price
2.00B
Potential new shares
Oct 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
2 Apr 2026Li (Alex) LiOther163.2M30.0M—3Y notice
2 Apr 2026Carl HagonOther—30.0M—3Y notice
2 Apr 2026Zoran GrujicOther—30.0M—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

27 July 2026Investor Webinar
26 July 2026$P$12M OFFTAKE AGREEMENT WITH LEADING OTC-PHARMACEUTICAL
9 June 2026Xenitra Investor Webinar
3 June 2026$P$1.1m in OPAL-Tokenised Product Sales in First 7 Weeks
1 June 2026$PXEN Appointed as Exclusive Biomiq Skincare China Distributor
19 May 2026Notice Under Section 708A
19 May 2026Application for quotation of securities - XEN
13 May 2026$PProduct sales of $500k in first month of OPAL token launch
7 May 2026Investor Presentation
6 May 2026Proposed issue of securities - XEN
6 May 2026$P$1.25m Raised to Support Next Phase of Growth
5 May 2026$PTrading Halt
4 May 2026$PPause in Trading
30 Apr 2026Change of Address
30 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
20 Apr 2026$POPAL token launch of EZZ products sells $100k in first week
15 Apr 2026$PQ3 Sales rise by over 305% to $8.3m
14 Apr 2026$PAcquisition of Fukang OTC Pharmacy
9 Apr 2026Change of Director's Interest Notice - ZG
9 Apr 2026Change of Director's Interest Notice - LL

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.